NCT00667355View on ClinicalTrials.gov

A Study of Adalimumab in Japanese Subjects With Active Ankylosing Spondylitis

PHASE3CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

May 31, 2009

Study Completion Date

January 31, 2011

Conditions
Ankylosing Spondylitis
Interventions
BIOLOGICAL

adalimumab

40 mg or 80 mg every other week, subcutaneous

Trial Locations (19)

Unknown

Site Reference # / Investigator 46791, Aichi

Site Reference # / Investigator 46789, Fukui

Site Reference # / Investigator 46798, Fukuoka

Site Reference # / Investigator 46799, Fukuoka

Site Reference # / Investigator 46796, Hiroshima

Site Reference # / Investigator 46782, Hokkaido

Site Reference # / Investigator 7297, Hokkaido

Site Reference # / Investigator 46795, Hyōgo

Site Reference # / Investigator 46797, Kagawa

Site Reference # / Investigator 46787, Kanagawa

Site Reference # / Investigator 46790, Nagano

Site Reference # / Investigator 46793, Osaka

Site Reference # / Investigator 46794, Osaka

Site Reference # / Investigator 46783, Saitama

Site Reference # / Investigator 46784, Saitama

Site Reference # / Investigator 46792, Shiga

Site Reference # / Investigator 46785, Tokyo

Site Reference # / Investigator 46786, Tokyo

Site Reference # / Investigator 46788, Toyama

Sponsors

Lead Sponsor

Abbott
All Listed Sponsors
collaborator

Eisai Co., Ltd.

INDUSTRY

lead

Abbott

INDUSTRY